摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-Hydroxy Etizolam | 52170-72-6

中文名称
——
中文别名
——
英文名称
9-Hydroxy Etizolam
英文别名
[7-(2-chlorophenyl)-4-ethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-13-yl]methanol
9-Hydroxy Etizolam化学式
CAS
52170-72-6
化学式
C17H15ClN4OS
mdl
——
分子量
358.8
InChiKey
RKOHSLBWMOPWFG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    91.5
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    9-Hydroxy Etizolam盐酸碳酸氢钠1H-吲哚-2-羰酰氯 在 ice 、 Brine 、 magnesium sulfate 、 silica gel 、 乙酸乙酯ethyl acetate n-hexane 作用下, 以 氯仿 为溶剂, 反应 19.0h, 以to give 0.015 g of N-(4-(3-(2-chlorobenzoyl)-5-ethylthiophen-2-yl)-3-hydroxymethyl[1,2,4]triazol-5-ylmethyl)indole-2-carboxamide的产率得到N-(4-(3-(2-chlorobenzoyl)-5-ethylthiophen-2-yl)-3-hydroxymethyl[1,2,4]triazol-5-ylmethyl)indole-2-carboxamide
    参考文献:
    名称:
    Thienylazole compound and thienotriazolodiazepine compound
    摘要:
    本发明提供了Thienylazole化合物(I)和thienotriazolodiazepine化合物(II),其化学式为##STR1##其中R.sup.1和R.sup.2是氢,卤素,C.sub.1-C.sub.5烷基等;--A.dbd.B--是--N.dbd.N--等;R.sup.3和R.sup.19是氢,C.sub.1-C.sub.5烷基等;Y是--NHCO--,--NHCONH--,--NHCOO--等;Z.sup.1和Z.sup.2是芳基,杂芳基等;Ar是卤素取代的苯基等;m为0或1-5的整数。本发明的化合物具有CCK拮抗作用和胃泌素拮抗作用,特别是对CCK-A受体具有强烈的拮抗作用,可用作中枢和外周神经系统疾病(如焦虑,精神分裂症等)和消化系统疾病(如胰腺炎,胃溃疡,肠炎,肠易激综合征,便秘等)的预防和治疗剂。
    公开号:
    US05760032A1
点击查看最新优质反应信息

文献信息

  • THIENYLAZOLE COMPOUND AND THIENOTRIAZOLODIAZEPINE COMPOUND
    申请人:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
    公开号:EP0776892A1
    公开(公告)日:1997-06-04
    Thienylazole compounds (I) and thienotriazolodiazepine compounds (II) of the formulas wherein R1 and R2 are hydrogen, halogen, C1-C5 alkyl and the like; -A=B-is -N=N- and the like; R3 and R19 are hydrogen, C1-C5 alkyl and the like; Y is -NHCO, -NHCONH-, -NHCOO- and the like; Z1 and Z2 are aryl, heteroaryl and the like; Ar is halogen-substituted phenyl and the like; and m is 0 or an integer of 1-5. The compounds of the present invention have CCK antagonistic action and gastrin antagonistic action, particularly potent antagonistic action against CCK-A receptor, and are useful as agents for the prophylaxis and treatment of central and peripheral nervous system diseases (e.g., anxiety, schizophrenia, and the like) and digestive diseases (e.g., pancreatitis, gastric ulcer, enterelcosis, irritable bowel syndrome, constipation, and the like).
    噻吩基氮唑化合物(I)和噻吩三唑并二氮杂卓化合物(II),其式如下 其中 R1 和 R2 是氢、卤素、C1-C5 烷基和类似物;-A=B- 是-N=N- 和类似物;R3 和 R19 是氢、C1-C5 烷基和类似物;Y 是-NHCO、-NHCONH-、-NHCOO- 和类似物;Z1 和 Z2 是芳基、杂芳基和类似物;Ar 是卤素取代的苯基和类似物;m 是 0 或 1-5 的整数。 本发明的化合物具有 CCK 拮抗作用和胃泌素拮抗作用,特别是对 CCK-A 受体具有强效的拮抗作用,可作为预防和治疗中枢和周围神经系统疾病(如焦虑症、精神分裂症等)和消化系统疾病(如胰腺炎、胃溃疡、肠梗阻、肠易激综合征、便秘等)的药物。
  • Thienylazole compound and thienotriazolodiazepine compound
    申请人:Yoshitomi Pharmaceutical Industries, Ltd.
    公开号:US05760032A1
    公开(公告)日:1998-06-02
    Thienylazole compounds (I) and thienotriazolodiazepine compounds (II) of the formulas ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen, halogen, C.sub.1 -C.sub.5 alkyl and the like; --A.dbd.B-- is --N.dbd.N-- and the like; R.sup.3 and R.sup.19 are hydrogen, C.sub.1 -C.sub.5 alkyl and the like; Y is --NHCO--, --NHCONH--, --NHCOO-- and the like; Z.sup.1 and Z.sup.2 are aryl, heteroaryl and the like; Ar is halogen-substituted phenyl and the like; and m is 0 or an integer of 1-5. The compounds of the present invention have CCK antagonistic action and gastrin antagonistic action, particularly potent antagonistic action against CCK-A receptor, and are useful as agents for the prophylaxis and treatment of central and peripheral nervous system diseases (e.g., anxiety, schizophrenia, and the like) and digestive diseases (e.g., pancreatitis, gastric ulcer, enterelcosis, irritable bowel syndrome, constipation, and the like).
    本发明提供了Thienylazole化合物(I)和thienotriazolodiazepine化合物(II),其化学式为##STR1##其中R.sup.1和R.sup.2是氢,卤素,C.sub.1-C.sub.5烷基等;--A.dbd.B--是--N.dbd.N--等;R.sup.3和R.sup.19是氢,C.sub.1-C.sub.5烷基等;Y是--NHCO--,--NHCONH--,--NHCOO--等;Z.sup.1和Z.sup.2是芳基,杂芳基等;Ar是卤素取代的苯基等;m为0或1-5的整数。本发明的化合物具有CCK拮抗作用和胃泌素拮抗作用,特别是对CCK-A受体具有强烈的拮抗作用,可用作中枢和外周神经系统疾病(如焦虑,精神分裂症等)和消化系统疾病(如胰腺炎,胃溃疡,肠炎,肠易激综合征,便秘等)的预防和治疗剂。
查看更多

同类化合物

阿帕泛 贝帕泛 苯他西泮 环氯唑仑 溴替唑仑 氯噻西泮 司替帕泛 去甲氯噻西泮; 去甲基氯噻西泮; 5-(2-氯苯基)-7-乙基-1,3-二氢-2H-噻吩并[2,3-e][1,4]二氮杂卓-2-酮 伊拉帕泛 乙替唑仑 alpha-羟基依替唑仑 [(R,S)-4-(4-氯苯基)-2,3,9-三甲基-6H-1-硫杂-5,7,8,9a-四氮杂-环戊环[e]氮杂-6-基]-乙酸叔丁酯 N-(4-叔-丁基苯基)-6-(2-氯苯基)-1-甲基-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲酰胺 7-氯-5-(2-氯苯基)-1,3-二氢-2H-噻吩并-(2,3-e)-(1,4)-二氮杂卓-2-硫酮 7-乙基-5-苯基-3,4-二氢噻吩并[3,2-f][1,4]二氮杂卓-2-酮 7-乙基-5-(2-氟苯基)-1,3-二氢-2H-噻吩并[2,3-e]-1,4-二氮杂卓-2-酮 6-(2-氯苯基)-1-甲基-N-[4-(三氟甲基)苯基]-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 6-(2-氯苯基)-1-甲基-N-(1-甲基-2-苯基乙基)-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 5,6-二氢-5-甲基-6-氧代-4H-i咪唑并[1,5-a]噻吩并[2,3-f][1,4]二氮杂-3-羧酸1,1-二甲基乙酯 4-甲基-3,4-二氢-1H-噻吩并[2,3-E][1,4]二氮杂-2,5-二酮 4-(2-氯苯基)-N-(2-羟基乙基)-9-甲基-6H-噻吩并(3,2-f)(1,2,4)三唑并(4,3-a)(1,4)二氮杂卓-2-丙酰胺 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸甲酯 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸 4-(2-氯苯基)-9-甲基-2-(4-吗啉-4-基-4-羰基丁基)-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓 3-噻丁烷酮,2-氯-2-(1-甲基乙基)- 3-[4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-基]-2-丙炔-1-醇 2-((6R)-4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F]的[1,2,4 (S)-4-(4-氯苯基)-N-(4-羟基苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-乙酰胺 (S)-2-(4-(4-氯苯基)-2-(羟甲基)-3,9-二甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3]-A][1,4]二氮杂卓-6-基)乙酸甲酯 (S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯 (-)-JQ-1; (R)-(-)2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂环庚烷-6-基)乙酸叔丁酯 (+)-JQ1羧酸 10-Amino-4H-2,5-dihydrothieno[3,4-b][1,5]benzodiazepine ethyl 5,6-dihydro-6-thioxo-4H-imidazo[1,5-a]thieno[2,3-f][1,4]diazepine-3-carboxylate ethyl 5,6-dihydro-6-oxo-4H-imidazo[1,5-a]thieno[2,3-f][1,4]diazepine-3-carboxylate 2-hexyl-4-(4-methylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[ 4,3-a][1,4]diazepine 2-hexyl-4-(2,4-dimethylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 2-hexyl-4-(3-methylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 7-hexyl-5-(2,5-dimethylphenyl)-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepin-2-one 2-hexyl-4-(2,5-dimethylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 2-hexyl-4-(3,4,5-trimethoxyphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 7-hexyl-5-(4-methylphenyl)-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepin-2-one 7-(2,3-dimethylphenyl)-4-hexyl-13-methyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaene 2-hexyl-4-(3,4-dimethylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 1-(4-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepine-4-yl)phenyl)urea 1-(4-((4-ethylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepine-4-yl)phenyl)urea 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepine-4-yl)phenyl)urea 5,6-dihydro-6-N,N-dimethylhydrazino-4H-pyrrolo<1,2-a>thieno<3,2-f><1,4>diazepin-4-one 2-(2-acetylhydrazino)-7-chloro-5-(2,6-difluorophenyl)-3H-thieno[2,3-e]-1,4-diazepine (S)-N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamide